Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Geers, DarylSablerolles, Roos S G
van Baarle, Debbie
Kootstra, Neeltje A
Rietdijk, Wim J R
Schmitz, Katharina S
Gommers, Lennert
Bogers, Susanne
Nieuwkoop, Nella J
van Dijk, Laura L A
van Haren, Eva
Lafeber, Melvin
Dalm, Virgil A S H
Goorhuis, Abraham
Postma, Douwe F
Visser, Leo G
Huckriede, Anke L W
Sette, Alessandro
Grifoni, Alba
de Swart, Rik L
Koopmans, Marion P G
van der Kuy, P Hugo M
GeurtsvanKessel, Corine H
de Vries, Rory D
Type
ArticleLanguage
en
Metadata
Show full item recordTitle
Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination.Published in
iScience 2022;26(1):105753PMID
36507223ae974a485f413a2113503eed53cd6c53
10.1016/j.isci.2022.105753
Scopus Count
Collections
Related articles
- Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming.
- Authors: Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, Visser LG, Geers D, Schmitz KS, Garcia Garrido HM, Koopmans MPG, Dalm VASH, Kootstra NA, Huckriede ALW, Lafeber M, van Baarle D, GeurtsvanKessel CH, de Vries RD, van der Kuy PHM, SWITCH Research Group
- Issue date: 2022 Mar 10
- Homologous and Heterologous Covid-19 Booster Vaccinations.
- Authors: Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, Rostad CA, Martin JM, Johnston C, Rupp RE, Mulligan MJ, Brady RC, Frenck RW Jr, Bäcker M, Kottkamp AC, Babu TM, Rajakumar K, Edupuganti S, Dobrzynski D, Coler RN, Posavad CM, Archer JI, Crandon S, Nayak SU, Szydlo D, Zemanek JA, Dominguez Islas CP, Brown ER, Suthar MS, McElrath MJ, McDermott AB, O'Connell SE, Montefiori DC, Eaton A, Neuzil KM, Stephens DS, Roberts PC, Beigel JH, DMID 21-0012 Study Group
- Issue date: 2022 Mar 17
- Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection.
- Authors: Moyo-Gwete T, Richardson SI, Keeton R, Hermanus T, Spencer H, Manamela NP, Ayres F, Makhado Z, Motlou T, Tincho MB, Benede N, Ngomti A, Baguma R, Chauke MV, Mennen M, Adriaanse M, Skelem S, Goga A, Garrett N, Bekker LG, Gray G, Ntusi NAB, Riou C, Burgers WA, Moore PL
- Issue date: 2023 Nov
- Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection.
- Authors: Moyo-Gwete T, Richardson SI, Keeton R, Hermanus T, Spencer H, Manamela NP, Ayres F, Makhado Z, Motlou T, Tincho MB, Benede N, Ngomti A, Baguma R, Chauke MV, Mennen M, Adriaanse M, Skelem S, Goga A, Garrett N, Bekker LG, Gray G, Ntusi NAB, Riou C, Burgers WA, Moore PL
- Issue date: 2023 Mar 15
- Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.
- Authors: Riou C, Bhiman JN, Ganga Y, Sawry S, Ayres F, Baguma R, Balla SR, Benede N, Bernstein M, Besethi AS, Cele S, Crowther C, Dhar M, Geyer S, Gill K, Grifoni A, Hermanus T, Kaldine H, Keeton RS, Kgagudi P, Khan K, Lazarus E, Le Roux J, Lustig G, Madzivhandila M, Magugu SFJ, Makhado Z, Manamela NP, Mkhize Q, Mosala P, Motlou TP, Mutavhatsindi H, Mzindle NB, Nana A, Nesamari R, Ngomti A, Nkayi AA, Nkosi TP, Omondi MA, Panchia R, Patel F, Sette A, Singh U, van Graan S, Venter EM, Walters A, Moyo-Gwete T, Richardson SI, Garrett N, Rees H, Bekker LG, Gray G, Burgers WA, Sigal A, Moore PL, Fairlie L
- Issue date: 2024